Dr. Andrew Brohl at ASCO 2023: Abstract No. 9534
2 Visningar
• 07/17/23
0
0
Bädda in
administrator
Prenumeranter
At ASCO 2023, Moffitt's Dr. Andrew Brohl discusses a phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant Merkel cell carcinoma and cutaneous squamous cell carcinoma.
Visa mer
Facebook-kommentarer
SORT BY-
Toppkommentarer
-
Senaste kommentarerna